FIU Discovery

The Time-Dependent Role of Bisphosphonates on Atherosclerotic Plaque Calcification.  Journal of Cardiovascular Development and Disease.  9.

S2 Heart Sound Detects Aortic Valve Calcification Independent of Hemodynamic Changes in Mice.  Frontiers in Cardiovascular Medicine.  9.

Abstract 14001: Using the S2 Sound as an Early Marker of Aortic Valve Calcification.  Circulation.  144:a14001-a14001.

Anti-apoptotic and Matrix Remodeling Actions of a Small Molecule Agonist of the Human Relaxin Receptor, ML290 in Mice With Unilateral Ureteral Obstruction.  Frontiers in Physiology.  12.

Tracking Acoustic and Electrophysiological Changes Associated with CKD-induced Cardiac and Valvular Remodeling in a Mouse Model.  Structural Heart.  5:23.

Abstract 17021: A Novel Human Relaxin Receptor Agonist, ML290, Attenuates Atherosclerosis- and Chronic Kidney Disease-Induced Vascular Calcification in Mice.  Circulation.  142.

Annexin-A1 deficiency exacerbates pathological remodelling of the mesenteric vasculature in insulin-resistant, but not insulin-deficient, mice.  British Journal of Pharmacology.  177:1677-1691.

Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights.  British Journal of Pharmacology.  177:217-233.

Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.  The FASEB Journal.  33:12435-12446.

Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.  Molecular and Cellular Endocrinology.  487:59-65.

Small molecule allosteric agonist of relaxin receptor ML290 demonstrates antifibrotic properties in liver fibrosis.  Endocrine Abstracts. 

Targeting the relaxin/insulin-like family peptide receptor 1 and 2 with small molecule compounds.  Molecular and Cellular Endocrinology.  487:40-44.

SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor Ml290 Demonstrates Antifibrotic Properties in Liver Fibrosis.  Journal of the Endocrine Society.  3:sat-035.

Recent developments in relaxin mimetics as therapeutics for cardiovascular diseases.  Current Opinion in Pharmacology.  45:42-48.

Endothelial dysfunction in the aorta of non-pregnant relaxin-deficient mice is not observed in pregnancy.  Placenta.  57:272.

Chronic NaHS treatment decreases oxidative stress and improves endothelial function in diabetic mice.  Diabetes and Vascular Disease Research.  14:246-253.

Serelaxin treatment reduces oxidative stress and increases aldehyde dehydrogenase-2 to attenuate nitrate tolerance.  Frontiers in Pharmacology.  8.

1,4-Anhydro-4-seleno-D-talitol (SeTal) protects endothelial function in the mouse aorta by scavenging superoxide radicals under conditions of acute oxidative stress.  Biochemical Pharmacology.  128:34-45.

Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.  Scientific Reports.  7.

B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).  European Journal of Pharmacology.  807:190-197.

Adverse vascular remodelling is more sensitive than endothelial dysfunction to hyperglycaemia in diabetic rat mesenteric arteries.  Pharmacological Research.  111:325-335.

Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta.  Pharmacological Research.  107:220-228.

Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin).  British Journal of Pharmacology.  173:1005-1017.

Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice.  American Journal of Physiology. Heart and Circulatory Physiology.  309:H285-H296.

Hydrogen sulfide protects endothelial nitric oxide function under conditions of acute oxidative stress in vitro..  Naunyn-Schmiedeberg's Archives of Pharmacology.  387:67-74.

OP15 Hydrogen sulfide protects endothelial function under conditions of oxidative stress.  Nitric Oxide - Biology and Chemistry.  31:s25.

Calcifying Extracellular Vesicles: Biology, Characterization, and Mineral Formation.  97-116.

Therapeutic Effects of a Small Molecule Agonist of the Relaxin Receptor in Mice with Unilateral Ureteral Obstruction.  The FASEB Journal.

A Biased Relaxin Receptor Agonist, ML290, Attenuates Atherosclerotic Calcification in Apolipoprotein E-deficient Mice.  The FASEB Journal.

Hydrogen sulfide as a vasculoprotective factor..  Medical Gas Research. 9.

Time-dependent Role of Bisphosphonates on Atherosclerotic Plaque Calcification

Epidermal Growth Factor Receptor Inhibition Prevents Caveolin-1-dependent Calcifying Extracellular Vesicle Biogenesis

Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.  Frontiers in Pharmacology.

Vascular actions of relaxin: nitric oxide and beyond.  British Journal of Pharmacology. 1002-1014.

Serelaxin: A Novel Therapeutic for Vascular Diseases.  Trends in Pharmacological Sciences. 498-507.